

25. TÜRK KLİNİK MİKROBİYOLOJİ VE İNFEKSİYON HASTALIKLARI KONGRESİ

KLİNİK MİKROBİYOLOJİDE YENİ NESİL DİZİLEME KURSU

Enfeksiyon Hastalıklarında Yeni Nesil Dizileme Önemi

Dr. Mert Ahmet KUSKUCU





Dataset

ncov
gisaid
global
6m

Date Range

2019-12-21 2020-05-15
PAUSE RESET

Color By

Clade

Filter Data

Type filter query here...

Tree



Layout

RECTANGULAR

RADIAL

UNROOTED

CLOCK

SCATTER


Branch Length

TIME DIVERGENCE

Phylogeny

Clade

- 19A 19B 20A 20C 20D



Geography


RESET ZOOM



Nucleotide diversity of genome

RESET LAYOUT

ENTROPY EVENTS



Infeksiyon Hastalığı Tanı



Ne Yapiyorum ?

Ne Yapardım ?

Ne Yapacağım ?

Infeksiyon Hastalığı Tanı;

Ne Yapardım, Ne Yapıyorum, Ne Yapacağım?

	Yöntem	Avantajları	Dezavantajları
Klasik Yaklaşım	Boyama Yöntemleri (Gram, EZN vb)	Hızlı Ucuz	Yüksek etken yükü olmadıkça düşük duyarlılık Düşük özgüllük
	Kültür Yöntemleri	Çok sayıda örnek çalışmaya uygun Ucuz Altın Standart	Antibiyotik ve antifungal kullanımıyla sınırlı duyarlılık Hassas organizmalar için sınırlı hassasiyet Viral testte sınırlı kullanım Özellikle aside dirençli bakteri ve mantar kültürlerinde sonuç almak için uzun zaman gerekli
	Serolojik Yöntemler	Akut enfeksiyondan sonra tanı potansiyeli Ucuz	Akut enfeksiyon sırasında negatif olabilir Humoral bağışıklık yetersizliklerinde yanlış negatifler Yanlış pozitifler

Infeksiyon Hastalığı Tanı;

Ne Yapardım, **Ne Yapiyorum**, Ne Yapacağım?


	Yöntem	Avantajları	Dezavantajları
Yeni Klasikler	Hedefe Yönelik PCR	Basit Hızlı Ucuz Kantitatitasyon yapabilme	Hipoteze bağlıdır Her zaman çalışmayabilecek primerler Genomun çok küçük bir kısmıyla sınırlıdır
	Çoklu PCR	Hızlı Birden fazla organizmayı tespit edebilir	Birden fazla amplicon içerdiği için görece olarak tek hedefli PCR'lara göre düşük duyarlılık Primer bağlanma bölgesi mutasyonları nedeni ile yalancı negatiflik
	MALDI-TOF	Yüksek özgüllük Kültür sonrası hızlı	Kültürde üremiş izolat gerektirir

Infeksiyon Hastalığı Tanı;

Ne Yapardım, Ne Yapıyorum, Ne Yapacağım?

	Yöntem	Avantajları	Dezavantajları
Yeni Yaklaşımlar	Klasik Dizileme için Hedefe Yönelik (16s, ITS) Universal PCR	Görece Ucuz Steril vücut sıvısında tek patojeni saptayabilir	Yüksek etken yükü olmadıkça düşük duyarlılık Çevresel kontaminasyon eğilimli
	NGS için Hedefe Yönelik Universal (16s, ITS) PCR	Steril vücut sıvısındaki patojenleri saptayabilir, Çoklu test olasılığı	Yüksek etken yükü olmadıkça düşük duyarlılık Kantitasyon olasılığı Pahalı ve zaman alıcı Kütüphane hazırlamak karmaşık
	Metagenom Analizi	Hipotezsiz veya tarafsız test Yeni veya beklenmedik organizmaların keşfi Kantitasyon potansiyeli Genomun herhangi bir bölümünü tespit etme yeteneği Konak ile ilgili bilgi sağlar	Pahalı Zaman alıcı Tüm genomlar için veritabanı mevcut değildir Çevresel kontaminasyon eğilimli

Yeni Nesil Dizileme, Genomik Çağda Enfeksiyon Hastalıkları Uzmanlığı




Tarafsız ve Hipotez Olmadan


Hypothesis-Free !!!

Tarafsız ve Hipotez Olmadan


WHOLE GENOME SEQUENCING (Direct Colony)



TARGETED SEQUENCING (Direct Sample)




SHOTGUN SEQUENCING (Direct Sample)



Metagenomik Tanı Yaklaşımı

İnsan Genomu




Steril
Örnekler


Floralı
Örnekler

Highlighting Clinical Metagenomics for Enhanced Diagnostic Decision-making: A Step Towards Wider Implementation

Jessica D. Forbes^{a,b,c}, Natalie C. Knox^c, Christy-Lynn Peterson^c, Aleisha R. Reimer^{c,*}




Ne Umduk? Ne Bulduk



Next-generation sequencing: what are the needs in routine clinical microbiology? A survey among clinicians involved in infectious diseases practice

Charlotte Michel^{1*}, Charlotte Martin², Pierre Smeesters^{3,4},
Jean-Christophe Goffard⁵, Thomas Demuyser⁶ and Marie Hallin⁷



Ne Umduk? Ne Bulduk

Next-generation sequencing: what are the needs in routine clinical microbiology? A survey among clinicians involved in infectious diseases practice

Charlotte Michel^{1*}, Charlotte Martin², Pierre Smeesters^{3,4},
Jean-Christophe Goffard⁵, Thomas Demuyser⁶ and Marie Hallin⁷

Background: The translation of Next-Generation Sequencing (NGS) from research to clinical microbiology is increasing rapidly, but its integration into routine clinical care struggles to catch-up. A challenge for clinical laboratories is that the substantial investments made in the required technologies and resources must meet both current and forthcoming needs.

Methods: To get a clinical perspective of these needs, we have sent a survey to infectious diseases clinicians of five hospitals, covering the following topics: NGS knowledge, expected syndromes and patients foreseen to benefit from NGS, and expected impact on antimicrobial prescription.



Results: According to clinicians, **benefits of NGS are mostly expected in neurological and respiratory infections diagnostics.**

Conclusion: **A better dialog between microbiologists and clinicians** about hopes and limits of NGS in microbiology may help identifying key investments needed for clinical laboratories, today and tomorrow.

Diagnostic Stewardship for Next-Generation Sequencing Assays in Clinical Microbiology

An Appeal for Thoughtful Collaboration

David C. Gaston, MD, PhD^{a,*}, Augusto Dulanto Chiang, MD^b, Kevin Dee, MD^b, Daniel Dulek, MD^c, Ritu Banerjee, MD, PhD^d, Romney M. Humphries, PhD^a



Metagenomics to Assist in the Diagnosis of Bloodstream Infection

Alexander L. Greninger^{1*} and Samia N. Naccache²

Prealitik	• Normal cilt florası • Antibiyotik kullanımı • Geçici bakteriyemi • mNGS doğrulaması için kullanılan fazla numuneler, steril olmayan kimya veya hematoloji bölümlerinde teknikler
Analitik	• Reaktifler (örn. elüsyon tamponları, nükleik asit ekstraksiyon kitleri, enzimler) sırasında kontamine olmuştur. çevresel viral, bakteriyel veya fungal kirleticilerle üretim • Kullanıcının normal florası veya potansiyel patojenlerin yayılması (gizli solunum veya ishal virüsleri) • Ekstraksiyon, ters transkripsiyon, zenginleştirme, kütüphane hazırlığı sırasında çapraz kontaminasyon • Önceden oluşturulmuş kitaplıklarla çapraz kontaminasyon • Aynı barkod şemasını kullanarak önceki çalışmalardan sızma • Aynı çalıştırmada farklı barkodlardan indeks atlama
Postanalitik	• Bildirilen patojenin kontaminant mı, normal flora mı yoksa kandan gelen bir patojen mi olduğunun belirlenmesi

Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing


Michael R. Wilson, MD, MAS; Brian D. O'Donovan, MS; Jeffrey M. Gelfand, MD, MAS; Hannah A. Sample, BS; Felicia C. Chow, MD, MAS;

Table 1. Clinical Characteristics of the 7 Participants

Participant No./Sex/Age, y	Final Diagnosis	Clinical Presentation	Disease Duration at Time of Diagnostic LP, mo	Length of Follow-up, mo
1/M/28	<i>Taenia solium</i>	Headache, diplopia	11	8
2/F/34	<i>T solium</i>	Headache, unilateral facial numbness and tinnitus, recurrent loss of consciousness	9	21
3/M/52	<i>Cryptococcus neoformans</i>	Seizures, coma	3	19
4/M/55	HIV-1	Dementia, cough, night sweats, weight loss	0.5	7
5/M/32	<i>Aspergillus oryzae</i>	Headache, dizziness, diplopia, unilateral facial weakness and numbness	7	1
6/F/10	<i>Histoplasma capsulatum</i>	Back pain followed by unilateral facial droop, headache, neck stiffness	6	3.5
7/F/26	<i>Candida dubliniensis</i>	Low back pain followed by saddle anesthesia and unilateral foot drop	20	1

Metagenomic Next-Generation Sequencing for Diagnosis of Infectious Encephalitis and Meningitis: A Large, Prospective Case Series of 213 Patients

Xiao-Wei Xing¹, Jia-Tang Zhang^{2,3*}, Yu-Bao Ma², Mian-Wa Wei Wang⁵, Xiao-Kun Qi⁶, Xiao-Yan Chen², Lei Wu², Xiao-Juan Du⁸, Hong-Fen Wang², Rong-Fei Wang², Fei Yang² a



Pathogen	SSRN	Coverage, %	Depth	
Viral encephalitis and/or meningitis (n = 23), SSRN ≥ 2				
Herpes simplex virus 1 (n = 9)	2,764 (2–27639)	57.9066 (0.0412–91)	2.99 (1–7.5)	PCR (n = 5), Positive HSV antibody (CLIA) (n = 9)
Herpes simplex virus 2 (n = 1)	4,311	90	6.5	Positive HSV antibody (CLIA)
Varicella-zoster virus (n = 5)	77 (6–3626)	4.3204 (0.2258–95.6227)	1 (1–2.47)	Skin herpes zoster (n = 4), PCR (n = 1)
Epstein-Barr virus (n = 6)	124.5 (4–3807)	6.8258 (0.1022–71.6965)	1 (1–2.39)	PCR (n = 3); Neuropathology (n = 1, DLBCL); Positive EBV antibody (n = 4)
Cytomegalovirus (n = 1)	4	0.081	1	CSF cytomegalovirus IgG (122.0 U/mL)
Human adenovirus B1 (n = 1)	2,467	62.309	9.84	Clinical evidence
Tuberculous meningitis (n = 12), GSRN ≥ 1				
<i>Mycobacterium tuberculosis</i> complex	4 (1–1046)	ND	ND	Xpert MTB/RIF (n = 3); A. TB or T-SPOT.TB (n = 4); Tuberculosis antibody (n = 1); Clinical evidence (n = 4)
Bacterial meningitis (n = 24), SSRN ≥ 5 or 10				
<i>Streptococcus pneumoniae</i> (n = 10)	2,488 (19–34711)	6.0112 (0.2236–66.8601)	1.31 (1–4.56)	Smear/culture (n = 4),
<i>Streptococcus pyogenes</i> (n = 1)	453	3.7	1	Smear
<i>Streptococcus intermedius</i> (n = 1)	592	5.2651	1	Clinical evidence
<i>Klebsiella pneumoniae</i> (n = 3)	15 (12–70)	0.0241 (0.0127–0.2979)	1 (1–1.59)	Culture (n = 3)
<i>Listeria monocytogenes</i> (n = 2)	43.5 (36–51)	0.1167 (0.0418–0.1915)	1.01 (1–1.02)	Culture (n = 2)
<i>Nocardia farcinica</i> (n = 1)	277	0.2631	1.16	Clinical evidence
<i>Brucella</i> (n = 1)	18 (GSRN)	ND	ND	RBPT(+) and SAT(+)
<i>Stenotrophomonas maltophilia</i> (n = 1)	288	0.7879	1	Clinical evidence
<i>Haemophilus influenzae</i> (n = 1)	12	0.1478	1	Clinical evidence
<i>Escherichia coli</i> (n = 1)	58	1.2399	1	Culture
<i>Aggregatibacter aphrophilus</i> (n = 1)	256	0.7625	4.61	Clinical evidence
<i>Neisseria meningitidis</i> (n = 1)	4543	44.2621	1.82	Clinical evidence
Fungal meningitis (n = 14), SSRN or GSRN ≥ 2				
<i>C. neoformans</i> s.l. (n = 10)	40.5 (2–177203)	0.01445 (0.0019–71)	1 (1–24)	India ink staining or culture for fungi
<i>C. gattii</i> s.l. (n = 5)	334 (7–71743)	0.1885 (0.0136–20)	1.02 (1–8.7)	India ink staining or culture for fungi
<i>Aspergillus</i> (n = 4)	6 (3–9) (GSRN)	ND	ND	Histopathology





A**B****B1****B2**

TABLE 2 | Comparison of the diagnostic efficacy of five positive mNGS criteria for viral encephalitis and/or meningitis (Definite, $n = 54$).


SSRN	Positive consistent rate	Negative consistent rate	Total consistent rate	AUC	SE	95% CI
≥ 1	0.444	0.848	0.734	0.646	0.047	0.554–0.738
≥ 2	0.426	0.891	0.760	0.659	0.047	0.566–0.751
≥ 3	0.407	0.899	0.760	0.653	0.047	0.560–0.746
≥ 5	0.370	0.899	0.760	0.634	0.048	0.541–0.728
≥ 10	0.315	0.928	0.755	0.621	0.048	0.527–0.715

SSRN, species-specific read number; AUC, area under the curve; SE, standard error; CI, confidence interval.



Diagnosis of Sepsis with Cell-free DNA by Next-Generation Sequencing Technology in ICU Patients

Yun Long,^{a,*} Yinxin Zhang,^{b,d,e,*} Yanping Gong,^{b,d,e,*} Ruixue Sun,^{b,d,e,*} Longxiang Su,^a Xin Lin,^{b,d,e}




equality of proportions ($p = 0.013$). In addition, 15 viral pathogens including CMV, EBV, HSV-1 and human parvovirus B19 were identified in 14 samples by NGS. Combined

analysis

Type	Pathogen	Strain identified		
		BC (+)	NGS (+)	BC and NGS
Gram-positive bacteria	<i>Enterococcus faecalis</i>	2	1	2
	<i>Enterococcus faecium</i>	1	3	3
	<i>Lactococcus lactis</i>	0	1	1
	<i>Staphylococcus aureus</i>	1	2	2
	<i>Acinetobacter baumannii</i>	2	1	2
Gram-negative bacteria	<i>Aeromonas hydrophila</i>	0	1	1
	<i>Bacteroides fragilis</i>	1	1	1
	<i>Citrobacter freundii</i>	1	1	1
	<i>Escherichia coli</i>	0	1	1
	<i>Klebsiella pneumoniae</i>	1	3	3
	<i>Pseudomonas aeruginosa</i>	1	2	2
	<i>Candida albicans</i>	1	0	1
	Total	11	17	20
Fungi				

Metagenomic next-generation sequencing aids the diagnosis of viral infections in febrile returning travellers

Hanna Jerome^{a,1}, Callum Taylor^{b,1}, Vattipally B. Sreenu^a, Tanya Klymenko^a,



Methods: Plasma samples from 40 returning travellers presenting with a fever of $\geq 38^{\circ}\text{C}$ were sequenced using MNGS on the Illumina MiSeq platform and compared with standard-of-care diagnostic assays.

Results: In total, 11/40 patients were diagnosed with a viral infection. Standard of care diagnostics re-

Retrospective clinical and microbiologic analysis of metagenomic next-generation sequencing in the microbiological diagnosis of cutaneous infectious granulomas



Hsingmei Liu^{1†}, Qiao Ran^{1,2†}, Jianchi Ma¹, Jing Zhang¹, Ni Tan^{1,3}, Liyan Xi¹, Xiqing Li¹, Junmin Zhang¹ and Sha Lu^{1*}

Clinical and diagnostic values of metagenomic next-generation sequencing for infection in hematology patients: a systematic review and meta-analysis




Yuhui Chen^{1†}, Jinjin Wang^{1†} and Ting Niu^{1*} 

Conclusion mNGS has high positive detection rates in hematology patients. mNGS can guide clinical antibiotic adjustments and improve prognosis, especially in China.

Conclusions mNGS could provide a potentially rapid and effective alternative detection method for diagnosis of cutaneous infectious granulomas and mNGS results may affect the clinical prognosis resulting from enabling the patients to initiate timely treatment.

A cell-free DNA metagenomic sequencing assay that integrates the host injury response to infection

Alexandre Pellan Cheng^a, Philip Burnham^a, John Richard Lee^{b,c}, Matthew Pellan Cheng^{d,e}, Manikkam Suthanthiran^{b,c}, Darshana Dadhania^{b,c,1,2}, and Iwijn De Vlaminc^{a,1,2}



The challenge of diagnostic metagenomics

Alexander L. Greninger


Diagnostic Metagenomics List

☐	NextSeq/HiSeq (+1 backup?)	\$250k
☐	initial validation costs	\$120k
☐	server/AWS time/storage	\$40k
☐	2 FTE MLS wet-lab	\$150k/yr
☐	1.5 FTE bioinformatician	\$150k/yr
☐	1 lab director (0.1 FTE)	\$10k/yr
☐	library prep/QC reagents	\$45k/yr
☐	sequencing reagents (1 run/wk)	\$80-120k/yr

Başlangıç : 410.000 \$

Yıllık: 435.000 \$ - 475.000 \$

*Test Başı Maliyet; 2.000-2500 \$



Teşekkürler...